(Q35202868)

7 August 2017

1 reference

title

Medicinal chemistry of target family-directed masterkeys (English)

1 reference

7 August 2017

Gerhard Müller

1

1 reference

7 August 2017

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

8

1 reference

7 August 2017

681-691

1 reference

7 August 2017

15

1 reference

Drug discovery: a historical perspective

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Drug discovery today - and tomorrow

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Stategic trends in the drug industry

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Genomic sciences and the medicine of tomorrow

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

The role of innovation in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

From the analyst's couch. Trends in development cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

As biotech turns 20...

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Comprehensive survey of combinatorial library synthesis: 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

New goals for the U.S. Human Genome Project: 1998-2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Too many targets, not enough target validation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

1 reference

7 January 2021

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Tifluadom, a kappa-opiate agonist, acts as a peripheral cholecystokinin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

An opioid benzodiazepine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Development of a virtual screening method for identification of "frequent hitters" in compound libraries

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Kinase inhibitors: not just for kinases anymore

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

The properties of known drugs. 1. Molecular frameworks

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Properties of known drugs. 2. Side chains

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

RECAP--retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Privileged molecules for protein binding identified from NMR-based screening

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Isolation of translactone-containing triterpenes with thrombin inhibitory activities from the leaves of Lantana camara

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Thrombin inhibitors based on [5,5] trans-fused indane lactams

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

The discovery of a potent, intracellular, orally bioavailable, long duration inhibitor of human neutrophil elastase--GW311616A a development candidate

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 1. The alpha-methyl-trans-lactam template

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Pyrrolidine-5,5-trans-lactams. 1. Synthesis and incorporation into inhibitors of hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

Pyrrolidine-5,5-trans-lactams. 2. The use of X-ray crystal structure data in the optimization of P3 and P4 substituents

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1359-6446%2803%2902781-8

1 reference

7 January 2021

10.1016/S1359-6446(03)02781-8

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12927511